REG - Roquefort Theraptcs. - Board Changes

Roquefort TherapeuticsAnnouncement

10/03/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250310:nRSJ9097Za&default-theme=true

RNS Number : 9097Z  Roquefort Therapeutics PLC  10 March 2025

10 March 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Board Changes

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, announces that as part of a planned
transition, Ajan Reginald has advised his intention to resign as CEO and
Director of the Company and Prof. Sir Martin Evans has also tendered his
resignation as Non-Executive Director, both of which are with effect from
close of business on 17 March 2025. Dr Darrin M Disley OBE, currently a
Non-Executive Director, will be appointed Interim Managing Director with
effect from close of business on 17 March 2025.

 

Darrin Disley is a seasoned life sciences entrepreneur with a history of value
creation in the UK market.  His most notable achievement is leading gene
editing company Horizon Discovery from start-up phase in 2007 to a £68
million AIM IPO in 2014 and growing the business to generate significant
revenues with a global presence before stepping down to pursue other interests
in 2018.  Horizon was eventually acquired by PerkinElmer in 2021 for a total
Enterprise value of £296 million.  Roquefort Therapeutics is pleased to have
Dr Disley leading the business and his significant expertise will be of
benefit to the Company going forward.

 

Mr Reginald's resignation is part of a planned transition as the Company
completes the execution of the first phase of its business strategy via
completion of the trade sales of its wholly-owned subsidiaries Lyramid Pty Ltd
("Lyramid") and Oncogeni Limited ("Oncogeni"). Ajan will remain a consultant
to the Company and Chairman of the Company's wholly owned subsidiary Oncogeni
in order to oversee the proposed sale of Oncogeni to The Nations Trust
Holding, as announced earlier today, and to oversee the sale of Lyramid to
Pleiades Pharma Ltd. Ajan has agreed to waive the notice period under his
service agreement.

 

Stephen West, Roquefort Therapeutics Chairman commented:

"I would like to thank Ajan for his contribution during his time as CEO of
Roquefort Therapeutics and am pleased that he is remaining as a consultant to
the business to oversee the Lyramid and Oncogeni transactions.  I would like
to wish Ajan and Sir Martin well with their future endeavours.  At the same
time I would like to welcome Darrin as Interim Managing Director and look
forward to working with him on communicating the forward strategy of the
Company, which will build upon the change in leadership and the successful
completion of the Lyramid and Oncogeni transactions."

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                      +44 (0)20 3918 8633
 Stephen West (Chairman)
 SP Angel Corporate Finance LLP (Broker)         +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Burson Buchanan (Public Relations)              +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                    +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Dr Darrin M Disley, OBE

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise
champion who has started, grown, or invested in over 40 start-up life science,
technology and social enterprises, raising US$600 million in business
financing and closing US$700 million in commercial deals. He was CEO of
Horizon Discovery Group plc for 11 years, during which he led the company from
start-up through a £68 million AIM IPO, and rapid scale-up powered by
multiple acquisitions of US peer companies to become a global market leader in
gene editing and gene modulation technologies. He was awarded a lifetime
Queen's Award for Enterprise Promotion in 2016 for his work in promoting
enterprise across the UK and appointed OBE in 2018 for his services to
business and enterprise in the healthcare sector.

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the
immunology and oncology markets prior to securing a value accretive exit.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical  anti-cancer and immunology assets.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASSSFIUEISELD